Anti-VEGF therapies can work through several mechanisms. Monoclonal antibodies like Bevacizumab bind to VEGF itself, preventing it from interacting with its receptors on endothelial cells. Small molecule inhibitors, on the other hand, target the VEGF receptors (VEGFR) directly, blocking the downstream signaling pathways that lead to angiogenesis. Both strategies aim to reduce the formation of new blood vessels in the tumor microenvironment.
